期刊名称：EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for publication of research from areas of Pharmaceutical technology, Drug delivery systems, Controlled release systems, Drug targeting, Physical pharmacy, Biopharmaceutics, Pharmacodynamics and pharmacokinetics, Drug development, Drug and prodrug design, Pharmaceutical biotechnology, Pharmaceutical analysis, Drug stability, Quality control, GMP, Regulatory aspects, Pharmaceutical packaging, and Phytochemistry.
The following types of papers are considered by the editors: Research Papers, Rapid Communications, Reviews, Technical Notes.
Audience
Pharmaceutical Scientists, Chemical Engineers, Pharmaceutical and Biopharmaceutical Scientists, Medicinal Chemists, Pharmacologists, Analytical Chemists, Clinical Pharmacologists, Pharmaceutical Engineers
Abstracting / Indexing
- BIOSIS
- CAB Abstracts
- Chemical Abstracts
- EMBASE
|
- International Pharmaceutical Abstracts
- Medline
- PASCAL M
- Science Citation Index
|
Instructions to Authors
The European Journal of Pharmaceutics and Biopharmaceutics considers full manuscripts for publication as research papers, notes and review articles. Submission requirements specify that papers should be original, unpublished and not under consideration for publication elsewhere. The scope of the journal includes pharmaceutics, pharmaceutical technology, biopharmaceutics, pharmacokinetics, controlled release systems, industrial pharmacy, drug delivery, quality control, GMP, regulatory aspects, analytical issues, microbiology and related fields.
Papers must be written in English. Organization of the manuscript must follow the style of the Journal. One original and three copies of the text with disk must be submitted. Please include full contact information - corresponding author name, e-mail address, telephone and fax numbers, and full postal address. Typing should be double spaced on A4 paper or equivalent 21.59 (27.94 cm). The pages should be numbered consecutively. Separate sheets should be used for the title page, abstract, tables and figures.
Papers from outside America should be sent to: Prof. Robert Gurny, School of Pharmacy, University of Geneva, 30, quai E.-Ansermet, CH-1211 Geneva 4, Switzerland; E-mail: ejpb@pharm.unige.ch
Papers from America should be sent directly to: Prof. James W. McGinity, The University of Texas at Austin, College of Pharmacy, Austin, TX 78712, USA.
Electronic Manuscripts
Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs.
After final acceptance for publication, your revised manuscript must be submitted again on disk, together with three identical printed hard copies, to the accepting Editor. It is important that the file on disk and the printed copies be identical.
The preferred file storage medium is a 3.5 inch disk in MS-DOS format, although other systems are acceptable, e.g., NEC and Apple (in this case, save your file in the usual manner; do not use the option 'save in MS-DOS format').
Ensure that the letter "l" and digit "1" (also letter "O" and digit "0") have been used properly, and format your article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the word processor format. If your word processor features the option to save files "in flat ASCII", please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and word processing package used, label the disk with your name and the name of the file on the disk.
Additional instructions on how to prepare your manuscript can be found at: http://authors.elsevier.com . More in-depth guidelines for submitting artwork/illustrations can be found at: http://authors.elsevier.com/artwork .
Review of manuscripts
Upon receipt, a manuscript will be peer-reviewed. The reviewers' relevant comments and the editor's decision will be communicated to the authors.
Research papers
TITLE
It should be carefully chosen to provide precise information about the contents and include important keywords. The title should be followed by the full name(s) of the author(s) and by his (her, their) affiliation(s). Different affiliations should be indicated by suitable superscripts.
To ensure identification of the corresponding author, please indicate full name, full postal address, e-mail address, phone and facsimile on the cover of the manuscript.
KEYWORDS
Indicate 5 to 10 English keywords. They should be carefully selected in order to improve accessibility of scientific information in the manuscript. Keywords commonly used in international abstracting services will be preferred.
ABSTRACT
It should contain a brief and clear description of the aim of the paper, its principal results and major conclusions (100--200 words). The abstract should include all keywords pertinent to the subject.
RESEARCH PAPERS
Should contain the following sections: Introduction, Theoretical Development (if applicable), Materials and Methods, Results, Discussion (or Results and Discussion) and References. For purely theoretical papers, appropriate sections may be selected.
INTRODUCTION
It should define the purpose of the research and reveal its connections with the principal work of other authors in the field.
MATERIALS AND METHODS
It should include materials, standard techniques and procedures relevant to the study. Published procedures and techniques should be cited unless significant modifications are involved. Exact specification of relevant materials and equipment must be given. Chemical terms must conform with IUPAC rules. Trademarks of commercial products must be labelled using a superscripted `(r)'. Names of products and equipment mentioned in the Materials and Methods section must be accompanied by the name of the manufacturer or distributor, location and state or country. This information must be stated in parentheses in the text, and not as a footnote. Any potential hazards connected with materials and procedures must be mentioned. A precise and detailed description should be given of those steps which are of vital importance in carrying out any repetition of the work. The Declarations of Helsinki and Tokyo for humans, and the European Community guidelines as accepted principles for the use of experimental animals, must be adhered to. Therefore, EJPB will only consider manuscripts that describe experiments that have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that the protocol complies with the particular recommendation and that approval of their protocols was obtained.
Equations must be part of the text and consecutively numbered on the right hand side using numbers in parentheses. References to equations in the text are also to be made with parentheses, e.g. using Eq. (3), etc.
Organic formulas, both in figures and in the text, should be numbered in boldface arabic numerals.
SI units must be used throughout.
RESULTS
Results may be presented in tables, figures or schemes which must be referred to in the accompanying text, using appropriate numbering, e.g. Fig. 1, Table 2.
DISCUSSION
It should focus on the interpretation of the results. It might be appropriate to combine RESULTS AND DISCUSSION in one section. If necessary at all, use CONCLUSIONS only to illustrate the general implication of the results and do not summarize the previous text.
TABLES
Tables must be presented on separate sheets in consecutive order using Arabic numerals. The table headings must include a descriptive title and additional information to make the table self-explanatory. Some information may be given by using lower-case letter designations referring to footnotes at the bottom of the table. Indicate SI units of measure in parentheses.
FIGURES
Figures must be presented on separate sheets in consecutive order using Arabic numerals. Each figure should be provided with an instructive title and explanatory information. The legend should be typed separately from the figures. To ensure identification of the figures, indicate figure number and name of author using soft pencil. Submit original drawings in black ink on good quality white paper. High-contrast photographs are equally acceptable. A limited number of colour photographs are accepted free of charge with prior permission from the Editor-in-Chief. Colour photographs above this number will only be reproduced at the expense of the author(s). The 2003 price for colour figures is 272 Euro for the first page and 182 Euro for subsequent pages. One original set is required with the submission. Numbering and lettering of figures should be carefully selected in order to ensure readability after photographic reduction of the figure. Use only standard symbols to mark datapoints. Explanation of curves and symbols should be in the legend rather that part of the drawing, unless this is detrimental to clarity. Indicate SI units of measure in parentheses.
CITATIONS
Citations of literature in the text must be presented in numerical order. Type numbers in parentheses and do not use superscripts. If names of authors are part of the text, use last names only.
REFERENCES
References must be arranged as follows:
[1] A.-L. Cornaz, P. Buri, Nasal mucosa as an absorption barrier, Eur. J. Pharm. Biopharm. 40 (1994) 261--270.
[5] C. Lanczos, Applied Analysis, Prentice-Hall, Englewood Cliffs, NJ, 1967, pp. 272--280.
[10] D.M. Barends, Stability of active ingredients, in: H. M¨¹ller, W.H. Oeser (Eds.), Drug Master Files, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany, 1992, pp. 121--128.
[14] E.A. Balazs, Ultrapure hyaluronic acid and the use thereof, U.S. Patent 4,141,973 (1979).
The system used by Chemical Abstracts (Chemical Abstracts Service Source Index) must be followed for the abbreviations of journals. Reference (4) is for patents, including the status, international country code, number of patent and year.
ACKNOWLEDGEMENTS
Acknowledgements of financial support, gifts, technical help or other assistance may be given in an unnumbered paragraph under this heading preceding the references.
Notes
The research and technical notes section of the journal (maximum 2500 words) is open to interesting results worthy of publication without requiring extensive introduction and discussion. This section should contain the following subheadings: Abstract, Introduction, Materials and Methods, Results and Discussion (combined). No more than 10 references should be used. Tables, figures and references are to be arranged according to research papers. Brevity of presentation is essential for this section. Five to 10 keywords should be provided.
Review articles
The organization and subdivision of review articles can be arranged at the author's discretion. Tables, figures and references are to be arranged according to research papers. An abstract, table of contents, and keywords are requested.
Copyright regulations for authors
Upon acceptance of an article by the Journal, author(s) will be asked to transfer the copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.
Correcting proofs and reprints
Elsevier Science is now sending PDF proofs to authors by e-mail for correction. If an author is unable to handle this process, regular print proofs will be sent. Elsevier Science will do everything possible to get the article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in one communication. Subsequent corrections will not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript will be allowed. Proofs should be returned to Elsevier Science within 48 hours.
EJPB has no page charges. Fifty offprints of each paper will be supplied free of charge to the corresponding author. Additional offprints can be ordered at prices shown on the offprint order form that accompanies the galley proofs.
Author enquiries
All questions arising after acceptance of a manuscript by the Editor, especially those relating to proofs, publication and reprints, should be directed to the Publisher.
Elsevier Science Ireland Ltd
Brookvale Plaza
East Park
Shannon, Co. Clare
Ireland
Tel: +353-61-709600
Fax: +353-61-709100
E-mail:authorsupport@elsevier.com
Please visit the Elsevier Science Author Gateway at http://authors.elsevier.com to track accepted articles and set up e-mail alerts to inform you of when the article status has changed. Information on artwork guidelines, copyright information, and frequently asked questions is also available.
A sample copy of the journal can be found on www.elsevier.com/locate/ejpb
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances made in the medical sciences, independent verification of diagnoses and drug dosages should be made.
Editorial Board
Editor-in-Chief:
R. Gurny, School of Pharmacy, University of Geneva, 30 Quai E.-Ansermet, CH-1211 Geneva 4, Switzerland; Email: ejpb@pharm.unige.ch
USA Editor:
J.W. McGinity, College of Pharmacy, Drug Dynamics Institute, The University of Texas at Austin, Austin, TX 78712, USA
Pacific Rim Editor:
Y. Kawashima, Gifu Pharmaceutical University, Gifu, Japan
European Editors:
A. Göpferich, Institute of Pharmacy, Pharmaceutical Technology, University of Regensburg, Germany
G. Lee, Institute for Pharmaceutical Technology, University of Erlangen-N¨¹rnberg, Erlangen, Germany
C.-M. Lehr, University of Saarland, Department of Biopharmaceutics and Pharmaceutical Technology, Saarbr¨¹cken, Germany
Assistant Editor:
M. Möller, School of Pharmacy, University of Geneva, 30, Quai E.-Ansermet, CH-1211 Geneva 4, Switzerland
Editorial Board: E. All¨¦mann, Geneva, Switzerland
M.J. Alonso, Santiago de Compostela, Spain
J.M. Anderson, Cleveland, OH, USA
L.P. Balant, Ch¨ºne-Bourg, Switzerland
S. Benita, Jerusalem, Israel
J.-P. Benoit, Angers, France
A. Bernkop-Schn¨¹rch, Vienna, Austria
R. Bodmeier, Berlin, Germany
G. Borchard, Leiden, The Netherlands
J. Breitenbach, Ludwigshafen, Germany
P. Breton, Paris, France
U. Conte, Pavia, Italy
P. Couvreur, Chatenay-Malabry, France
R. Daniels, Braunschweig, Germany
F. Delie-Salmon, Geneva, Switzerland
E. Doelker, Geneva, Switzerland
J.B. Dressman, Frankfurt/M., Germany
P. Esposito, Colleretto Giacosa, Italy
B. Gander, Z¨¹rich, Switzerland
M. Gonzalez, Weston, FL, USA
R.H. Guy, Geneva, Switzerland
J. Hadgraft, Chatham Marine, UK
J.A. Hubbell, Z¨¹rich, Switzerland
H.E. Junginger, Leiden, The Netherlands
T. Kissel, Marburg, Germany
P. Kleinebudde, D¨¹sseldorf, Germany
J. Kopecek, Salt Lake City, UT, USA
J. Kreuter, Frankfurt/M., Germany
V.H.L. Lee, Mountain View, CA, USA
J.-C. Leroux, Montr¨¦al, PQ, Canada
H. Leuenberger, Basel, Switzerland
H. Lindner, Copenhagen, Denmark
F.W.H.M. Merkus, Leiden, The Netherlands
B.W. M¨¹ller, Kiel, Germany
R.H. M¨¹ller, Berlin, Germany
C.C. M¨¹ller-Goyman, Braunschweig, Germany
T. Nagai, Tokyo, Japan
R.H.H. Neubert, Halle, Germany
N.A. Peppas, Austin, TX, USA
B. Plazonnet, Clemont-Ferrand, France
V. Pr¨¦at, Brussels, Belgium
J.R. Robinson, Madison, WI, USA
R. Schubert, Freiburg, Germany
K.J. Tojo, Fukuoka, Japan
V. Torchilin, Boston, MA, USA
C. Valenta, Vienna, Austria
G. Walsh, Limerick, Ireland
W. Weitschies, Greifswald, Germany
C.G. Wilson, Glasgow, U.K.
G. Winter, Munich, Germany
A. Zimmer, Graz, Austria
|
